Group 1 - The price target for EUDA Health has been lowered from $6 to $2.75 while maintaining a Buy rating on the shares [1] - The revenue estimate for EUDA Health has been revised down to $27.23 million from $43.05 million due to a reduction in Helixe bottles sold in 2026, decreasing from 105,000 to 50,000 [1] - The issuance of 12.5 million shares in late February has had a dilutive effect on the company's EPS estimates [1]